Clinical trial
Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That…
NCT00275093 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00275093 |
|---|---|
| Title | Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function |
| Official title | A Phase I Pharmacokinetic and Pharmacodynamic Study of Temsirolimus (CCI-779) in Patients With Advanced Malignancies and Normal and Impaired Liver Function: An NCI Organ Dysfunction Working Group Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatic Complications, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | temsirolimus, laboratory biomarker analysis, pharmacological study |
| Enrollment | 130 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2008 |
| First posted | Jan 11, 2006 |
| Last update posted | Jan 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: